Episode
From ASH 2025 to the Clinic: Global Perspectives on Evolving BTK Therapies in Relapsed/Refractory CLL
- Published
- Mar 11, 2026
- Duration seconds
- 1824
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/from-ash-2025-to-the-clinic-global-perspectives-on-evolving-btk-therapies-in-relapsed-refractory-cll/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/from-ash-2025-to-the-clinic-global-perspectives-on-evolving-btk-therapies-in-relapsed-refractory-cll.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
This episode features Matthew S. Davids, MD, MMSc; Nelson Hamerschlak, MD, PhD; and Stephen Stilgenbauer, MD, discussing key conference highlights from the 2025 ASH Annual Meeting, with a focus on emerging BTK-targeted therapies in relapsed/refractory CLL. They share global perspectives on real-world use, sequencing strategies, safety considerations, and how new data may shape future clinical practice.